Replies to post #10735 on Curative Biotechnology Inc (CUBT)

[Prudent Capitalist]

Thanks for the information.

[HokieHead]

Thanks Gizmachi, I see you are Jon from your prior posts.

Seems Paul M. Michaels, the new officer, has some serious credentials. He negotiated a deal with Teva Pharmaceuticals, which trades on the big boards with a $15 billion market cap, Inabata trades on the Tokyo Exchange with a market cap of $7 billion.

Bio from Inabata Pharmaceuticals about him, this guy is big-time.

Inabata Pharmaceuticals becomes a significant provider of pharmaceuticals and API and merges with Sumitomo Pharmaceuticals in 1983. Licensing activity begins in 1996 with Sumitomo Pharmaceuticals, through the negotiations of Investment Banker, Paul M. Michaels, licenses Ambisome and Danisome for the Asian marketplace from a U.S. Pharmaceutical company. This is the beginning of business licensing U.S. developed drugs for the Japanese market. Additionally, an Orphan drug business is created with the assistance of Paul M. Michaels with his Japanese counterparts called Nobelpharma. Co.Ltd. The first licensed product, from Teva Pharmaceuticals USA, is for the treatment of Wilson's disease in Japan. This transaction was negotiated and completed by Paul Michaels.

[Prudent Capitalist]

Thanks Jon. And congrats. Are you at liberty to disclose the share price of the purchase of the controlling shares?

[rstar]

thank you! great work